Batth I S, Mitra A, Manier S, Ghobrial I M, Menter D, Kopetz S, Li S
Department of Pediatrics - Research, The University of Texas MD Anderson Cancer Center, Houston, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
Ann Oncol. 2017 Mar 1;28(3):468-477. doi: 10.1093/annonc/mdw619.
Current trajectory of clinical care is heading in the direction of personalized medicine. In an ideal scenario, clinicians can obtain extensive diagnostic and prognostic information via minimally-invasive assays. Information available in the peripheral blood has the potential to bring us closer to this goal. In this review we highlight the contributions of circulating tumor cells and circulating tumor DNA and RNA (ctDNA/ctRNA) towards cancer therapeutic field. We discuss clinical relevance, summarize available and upcoming technologies, and hypothesize how future care could be impacted by a combined study.
当前临床护理的发展轨迹正朝着个性化医疗的方向前进。在理想情况下，临床医生可以通过微创检测获得广泛的诊断和预后信息。外周血中可用的信息有可能使我们更接近这一目标。在这篇综述中，我们强调循环肿瘤细胞以及循环肿瘤DNA和RNA（ctDNA/ctRNA）对癌症治疗领域的贡献。我们讨论其临床相关性，总结现有和即将出现的技术，并推测联合研究将如何影响未来的医疗护理。
